Lymphoma & CLL Trials

What novel targeted therapies are currently under investigation for R/R CLL?

During the 2021 ASCO Annual Meeting, the Lymphoma Hub spoke with Constantine Tam, Peter MacCallum Cancer Centre, Melbourne,...

Acalabrutinib meets primary endpoint in ELEVATE-RR trial for patients with R/R CLL

On January 25, 2021, it was announced that acalabrutinib has met its primary endpoint of non-inferior...

Positive effect on HRQoL and symptom severity with liso-cel in patients with R/R LBCL

Lisocabtagene maraleucel (liso-cel), a CD19-directed chimeric antigen receptor (CAR) T-cell therapy for the...

FDA approves lisocabtagene maraleucel for R/R large B-cell lymphoma

On February 5, 2021, it was announced that the U.S. Food and Drug Administration (FDA) approved lisocabtagene maraleucel (liso-cel),...

CHRONOS-3: Copanlisib plus rituximab in patients with relapsed indolent non-Hodgkin lymphoma

The standard treatment for relapsed indolent non-Hodgkin lymphomas is rituximab, which has emerged as an...

Phase III CHRONOS-3 study evaluating copanlisib and rituximab combination meets primary endpoint

Phase III CHRONOS-3 study, evaluating copanlisib in combination with rituximab for relapsed iNHL, meets...

Zanubrutinib granted priority review by the FDA for the treatment of adult patients with R/R MZL

On May 19, 2021, the U.S. Food and Drug Administration (FDA) accepted the supplemental new drug...

Novel targeted therapies for R/R marginal zone lymphoma

It has been challenging to define an optimal therapeutic approach for relapsed patients with marginal zone lymphoma (MZL) due to disease...